{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:51Z","timestamp":1793155731517,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016266","name":"Magyar T\u00fcd\u0151gy\u00f3gy\u00e1sz T\u00e1rsas\u00e1g","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","award":["\u00daNKP-21-5 \u00daNKP-20-5"],"award-info":[{"award-number":["\u00daNKP-21-5 \u00daNKP-20-5"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Spingosine-1-phosphate (S1P) and ceramides are bioactive sphingolipids that influence cancer cell fate. Anti-ceramide antibodies might inhibit the effects of ceramide. The aim of this study was to assess the potential role of circulating S1P and anti-ceramide antibody as biomarkers in non-small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited 66 subjects (34 controls and 32 patients with NSCLC). Patient history and clinical variables were taken from all participants. Venous blood samples were collected to evaluate plasma biomarkers. If bronchoscopy was performed, bronchial washing fluid (BWF) was also analyzed. We measured the levels of S1P and anti-ceramide antibody with ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>S1P levels were significantly higher in the NSCLC group (3770.99 \u00b1 762.29\u00a0ng\/mL vs. 366.53 \u00b1 249.38\u00a0ng\/mL, patients with NSCLC vs. controls, respectively, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Anti-ceramide antibody levels were significantly elevated in the NSCLC group (278.70 \u00b1 19.26\u00a0ng\/mL vs. 178.60 \u00b1 18\u00a0ng\/mL, patients with NSCLC vs. controls, respectively, <jats:italic>p<\/jats:italic> = 0.007). Age or BMI had no significant effect on anti-ceramide antibody or S1P levels. BWF samples had higher levels of anti-ceramide antibody (155.29 \u00b1 27.58\u00a0ng\/mL vs. 105.87 \u00b1 9.99\u00a0ng\/mL, patients with NSCLC vs. controls, respectively, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Overall survival (OS) was 13.36 months. OS was not affected by anti-ceramide antibody or S1P levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher levels of S1P and anti-ceramide antibody were associated with active cancer. These results suggest that sphingolipid alterations might be important features of NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/pore.2024.1611929","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:12:45Z","timestamp":1736136765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer"],"prefix":"10.3389","volume":"30","author":[{"given":"Lilla","family":"B\u0171di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m Domonkos","family":"T\u00e1rnoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid L\u00e1szl\u00f3","family":"T\u00e1rnoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Bikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.soc.2019.08.002","article-title":"Precision medicine in lung cancer treatment","volume":"29","author":"Shah","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1158\/0008-5472.CAN-13-0661","article-title":"Targeting the tumor microenvironment: from understanding pathways to effective clinical trials","volume":"73","author":"Fang","year":"2013","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc1411","article-title":"Biologically active sphingolipids in cancer pathogenesis and treatment","volume":"4","author":"Ogretmen","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbior.2013.10.001","article-title":"Sphingosine-1-phosphate in chronic intestinal inflammation and cancer","volume":"54","author":"Nagahashi","year":"2014","journal-title":"Adv Biol Regul"},{"key":"B8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd4099","article-title":"Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond","volume":"12","author":"Kunkel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21873\/anticanres.13078","article-title":"Bioactive sphingolipids as biomarkers predictive of disease severity and treatment response in cancer: current status and translational challenges","volume":"39","author":"Sedi\u0107","year":"2019","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1111\/cas.13802","article-title":"The role of sphingosine-1-phosphate in inflammation and cancer progression","volume":"109","author":"Nagahashi","year":"2018","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume-title":"Sphingolipids as signaling and regulatory molecules","author":"Gault","year":"2010"},{"key":"B12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.3390\/ijms16035076","article-title":"Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate","volume":"16","author":"Ueda","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JOE-13-0388","article-title":"Role of sphingolipids in oestrogen signalling in breast cancer cells: an update","volume":"220","author":"Sukocheva","year":"2014","journal-title":"J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbalip.2013.09.007","article-title":"Sphingolipids in colon cancer","volume":"1841","author":"Garc\u00eda-Barros","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10555-011-9304-1","article-title":"Sphingolipids in cancer","volume":"30","author":"Furuya","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.36849\/JDD.5543","article-title":"Implications of serum anti-ceramide antibodies and interleukin 4 on nerve damage and physical impairments among leprotic patients: a case-controlled study","volume":"21","author":"Zaky","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1172\/JCI59920","article-title":"Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice","volume":"122","author":"Rotolo","year":"2012","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-14-2031","article-title":"Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B20","first-page":"253","volume-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"key":"B22","volume-title":"Reports of the surgeon general. The Health consequences of smoking\u201450 Years of progress: a report of the surgeon general","year":"2014"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4806541","DOI":"10.1155\/2017\/4806541","article-title":"The role of sphingosine-1-phosphate and ceramide-1-phosphate in inflammation and cancer","volume":"2017","author":"Hait","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1074\/jbc.M116.762377","article-title":"Sphingosine and sphingosine kinase 1 involvement in endocytic membrane trafficking","volume":"292","author":"Lima","year":"2017","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1055-9965.1185.13.7","article-title":"Lysophospholipids are potential biomarkers of ovarian cancer","volume":"13","author":"Sutphen","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18095","DOI":"10.18632\/oncotarget.7741","article-title":"Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma","volume":"7","author":"Grammatikos","year":"2016","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-12-1424","article-title":"Plasma sphingolipids and lung cancer: a population-based, nested case-control study","volume":"22","author":"Alberg","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103301","DOI":"10.1016\/j.ebiom.2021.103301","article-title":"A circular network of coregulated sphingolipids dictates lung cancer growth and progression","volume":"66","author":"Meng","year":"2021","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"183624","DOI":"10.1155\/2015\/183624","article-title":"Biomarker identification and pathway analysis by serum metabolomics of lung cancer","volume":"2015","author":"Chen","year":"2015","journal-title":"Biomed Res Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.biochi.2019.01.018","article-title":"Emergence of membrane sphingolipids as a potential therapeutic target","volume":"158","author":"Sahu","year":"2019","journal-title":"Biochimie"},{"key":"B35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.bbalip.2013.09.005","article-title":"Autophagy paradox and ceramide","volume":"1841","author":"Jiang","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.3390\/ijms22126492","article-title":"The role of sphingolipids in cancer immunotherapy","volume":"22","author":"Giussani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1054\/drup.2001.0225","article-title":"Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance","volume":"4","author":"Ogretmen","year":"2001","journal-title":"Drug Resist Updat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1124\/jpet.106.101949","article-title":"Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo","volume":"317","author":"Senkal","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/jpet.112.199216","article-title":"LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria","volume":"344","author":"Beckham","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2010-02-271080","article-title":"Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia","volume":"116","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.cllc.2018.02.002","article-title":"Treatment patterns and clinical outcomes among metastatic non\u2013small-cell lung cancer patients treated in the community practice setting","volume":"19","author":"Nadler","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1611929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:12:49Z","timestamp":1736136769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1611929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":42,"alternative-id":["10.3389\/pore.2024.1611929"],"URL":"https:\/\/doi.org\/10.3389\/pore.2024.1611929","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1611929"}}